TGBC24TKB |
Growth inhibition assay |
|
|
Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50=1.03831μM |
SANGER |
BL-41 |
Growth inhibition assay |
|
|
Inhibition of human BL-41 cell growth in a cell viability assay, IC50=1.00013μM |
SANGER |
NOS-1 |
Growth inhibition assay |
|
|
Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=0.95045μM |
SANGER |
HOP-62 |
Growth inhibition assay |
|
|
Inhibition of human HOP-62 cell growth in a cell viability assay, IC50=0.91599μM |
SANGER |
TE-12 |
Growth inhibition assay |
|
|
Inhibition of human TE-12 cell growth in a cell viability assay, IC50=0.88831μM |
SANGER |
SW872 |
Growth inhibition assay |
|
|
Inhibition of human SW872 cell growth in a cell viability assay, IC50=0.86458μM |
SANGER |
SW982 |
Growth inhibition assay |
|
|
Inhibition of human SW982 cell growth in a cell viability assay, IC50=0.85819μM |
SANGER |
Daudi |
Growth inhibition assay |
|
|
Inhibition of human Daudi cell growth in a cell viability assay, IC50=0.71411μM |
SANGER |
PF-382 |
Growth inhibition assay |
|
|
Inhibition of human PF-382 cell growth in a cell viability assay, IC50=0.70763μM |
SANGER |
NCI-H1648 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50=0.51582μM |
SANGER |
VA-ES-BJ |
Growth inhibition assay |
|
|
Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50=0.46261μM |
SANGER |
RCC10RGB |
Growth inhibition assay |
|
|
Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50=0.42631μM |
SANGER |
SW954 |
Growth inhibition assay |
|
|
Inhibition of human SW954 cell growth in a cell viability assay, IC50=0.37163μM |
SANGER |
SNB75 |
Growth inhibition assay |
|
|
Inhibition of human SNB75 cell growth in a cell viability assay, IC50=0.35774μM |
SANGER |
IST-MES1 |
Growth inhibition assay |
|
|
Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50=0.35723μM |
SANGER |
OS-RC-2 |
Growth inhibition assay |
|
|
Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=0.35011μM |
SANGER |
SW684 |
Growth inhibition assay |
|
|
Inhibition of human SW684 cell growth in a cell viability assay, IC50=0.32588μM |
SANGER |
COLO-829 |
Growth inhibition assay |
|
|
Inhibition of human COLO-829 cell growth in a cell viability assay, IC50=0.31212μM |
SANGER |
NTERA-S-cl-D1 |
Growth inhibition assay |
|
|
Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50=0.28855μM |
SANGER |
TE-15 |
Growth inhibition assay |
|
|
Inhibition of human TE-15 cell growth in a cell viability assay, IC50=0.24276μM |
SANGER |
MFH-ino |
Growth inhibition assay |
|
|
Inhibition of human MFH-ino cell growth in a cell viability assay, IC50=0.23925μM |
SANGER |
TE-8 |
Growth inhibition assay |
|
|
Inhibition of human TE-8 cell growth in a cell viability assay, IC50=0.23924μM |
SANGER |
MZ1-PC |
Growth inhibition assay |
|
|
Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50=0.22716μM |
SANGER |
A498 |
Growth inhibition assay |
|
|
Inhibition of human A498 cell growth in a cell viability assay, IC50=0.18945μM |
SANGER |
HUTU-80 |
Growth inhibition assay |
|
|
Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=0.17529μM |
SANGER |
LB831-BLC |
Growth inhibition assay |
|
|
Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50=0.12715μM |
SANGER |
RXF393 |
Growth inhibition assay |
|
|
Inhibition of human RXF393 cell growth in a cell viability assay, IC50=0.10633μM |
SANGER |
MPP-89 |
Growth inhibition assay |
|
|
Inhibition of human MPP-89 cell growth in a cell viability assay, IC50=0.08229μM |
SANGER |
KS-1 |
Growth inhibition assay |
|
|
Inhibition of human KS-1 cell growth in a cell viability assay, IC50=0.07758μM |
SANGER |
LB1047-RCC |
Growth inhibition assay |
|
|
Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=0.07592μM |
SANGER |
Becker |
Growth inhibition assay |
|
|
Inhibition of human Becker cell growth in a cell viability assay, IC50=0.06381μM |
SANGER |
LB996-RCC |
Growth inhibition assay |
|
|
Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50=0.05668μM |
SANGER |
D-336MG |
Growth inhibition assay |
|
|
Inhibition of human D-336MG cell growth in a cell viability assay, IC50=0.04681μM |
SANGER |
LB2518-MEL |
Growth inhibition assay |
|
|
Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50=0.04667μM |
SANGER |
LC-2-ad |
Growth inhibition assay |
|
|
Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50=0.02033μM |
SANGER |
NCI-SNU-16 |
Growth inhibition assay |
|
|
Inhibition of human NCI-SNU-16 cell growth in a cell viability assay, IC50=0.01572μM |
SANGER |
A704 |
Growth inhibition assay |
|
|
Inhibition of human A704 cell growth in a cell viability assay, IC50=0.001268μM |
SANGER |
DOHH-2 |
Growth inhibition assay |
|
|
Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50=0.0005969μM |
SANGER |
BV-173 |
Growth inhibition assay |
|
|
Inhibition of human BV-173 cell growth in a cell viability assay, IC50=0.0005143μM |
SANGER |
K-562 |
Growth inhibition assay |
|
|
Inhibition of human K-562 cell growth in a cell viability assay, IC50=0.0001617μM |
SANGER |
BL-70 |
Growth inhibition assay |
|
|
Inhibition of human BL-70 cell growth in a cell viability assay, IC50=0.0000472μM |
SANGER |
CTV-1 |
Growth inhibition assay |
|
|
Inhibition of human CTV-1 cell growth in a cell viability assay, IC50=0.0000318μM |
SANGER |
MEG-01 |
Growth inhibition assay |
|
|
Inhibition of human MEG-01 cell growth in a cell viability assay, IC50=0.0000163μM |
SANGER |
EoL-1-cell |
Growth inhibition assay |
|
|
Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50=0.0000095μM |
SANGER |
LAMA-84 |
Growth inhibition assay |
|
|
Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=0.0000038μM |
SANGER |
EM-2 |
Growth inhibition assay |
|
|
Inhibition of human EM-2 cell growth in a cell viability assay, IC50=0μM |
SANGER |
KGN |
Growth inhibition assay |
|
|
Inhibition of human KGN cell growth in a cell viability assay, IC50=1.0521μM |
SANGER |
TK10 |
Growth inhibition assay |
|
|
Inhibition of human TK10 cell growth in a cell viability assay, IC50=1.08418μM |
SANGER |
GB-1 |
Growth inhibition assay |
|
|
Inhibition of human GB-1 cell growth in a cell viability assay, IC50=1.16064μM |
SANGER |
GCIY |
Growth inhibition assay |
|
|
Inhibition of human GCIY cell growth in a cell viability assay, IC50=1.2301μM |
SANGER |
LXF-289 |
Growth inhibition assay |
|
|
Inhibition of human LXF-289 cell growth in a cell viability assay, IC50=1.27256μM |
SANGER |
RL95-2 |
Growth inhibition assay |
|
|
Inhibition of human RL95-2 cell growth in a cell viability assay, IC50=1.32436μM |
SANGER |
SW962 |
Growth inhibition assay |
|
|
Inhibition of human SW962 cell growth in a cell viability assay, IC50=1.33742μM |
SANGER |
HT-144 |
Growth inhibition assay |
|
|
Inhibition of human HT-144 cell growth in a cell viability assay, IC50=1.44517μM |
SANGER |
IST-SL2 |
Growth inhibition assay |
|
|
Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50=1.47421μM |
SANGER |
NB6 |
Growth inhibition assay |
|
|
Inhibition of human NB6 cell growth in a cell viability assay, IC50=1.69698μM |
SANGER |
SF126 |
Growth inhibition assay |
|
|
Inhibition of human SF126 cell growth in a cell viability assay, IC50=1.73178μM |
SANGER |
BOKU |
Growth inhibition assay |
|
|
Inhibition of human BOKU cell growth in a cell viability assay, IC50=1.80527μM |
SANGER |
BB30-HNC |
Growth inhibition assay |
|
|
Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50=1.85472μM |
SANGER |
KLE |
Growth inhibition assay |
|
|
Inhibition of human KLE cell growth in a cell viability assay, IC50=1.86232μM |
SANGER |
MLMA |
Growth inhibition assay |
|
|
Inhibition of human MLMA cell growth in a cell viability assay, IC50=1.9231μM |
SANGER |
KINGS-1 |
Growth inhibition assay |
|
|
Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50=1.96897μM |
SANGER |
ES6 |
Growth inhibition assay |
|
|
Inhibition of human ES6 cell growth in a cell viability assay, IC50=2.05401μM |
SANGER |
SH-4 |
Growth inhibition assay |
|
|
Inhibition of human SH-4 cell growth in a cell viability assay, IC50=2.12055μM |
SANGER |
EB-3 |
Growth inhibition assay |
|
|
Inhibition of human EB-3 cell growth in a cell viability assay, IC50=2.15824μM |
SANGER |
KURAMOCHI |
Growth inhibition assay |
|
|
Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50=2.24236μM |
SANGER |
D-263MG |
Growth inhibition assay |
|
|
Inhibition of human D-263MG cell growth in a cell viability assay, IC50=2.28853μM |
SANGER |
SF268 |
Growth inhibition assay |
|
|
Inhibition of human SF268 cell growth in a cell viability assay, IC50=2.48682μM |
SANGER |
NB17 |
Growth inhibition assay |
|
|
Inhibition of human NB17 cell growth in a cell viability assay, IC50=2.62875μM |
SANGER |
DMS-114 |
Growth inhibition assay |
|
|
Inhibition of human DMS-114 cell growth in a cell viability assay, IC50=2.79022μM |
SANGER |
MC116 |
Growth inhibition assay |
|
|
Inhibition of human MC116 cell growth in a cell viability assay, IC50=2.85704μM |
SANGER |
MZ2-MEL |
Growth inhibition assay |
|
|
Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50=3.08643μM |
SANGER |
GI-ME-N |
Growth inhibition assay |
|
|
Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50=3.25166μM |
SANGER |
697 |
Growth inhibition assay |
|
|
Inhibition of human 697 cell growth in a cell viability assay, IC50=3.39644μM |
SANGER |
ACN |
Growth inhibition assay |
|
|
Inhibition of human ACN cell growth in a cell viability assay, IC50=4.22607μM |
SANGER |
TE-10 |
Growth inhibition assay |
|
|
Inhibition of human TE-10 cell growth in a cell viability assay, IC50=4.2795μM |
SANGER |
LS-123 |
Growth inhibition assay |
|
|
Inhibition of human LS-123 cell growth in a cell viability assay, IC50=4.35584μM |
SANGER |
TE-9 |
Growth inhibition assay |
|
|
Inhibition of human TE-9 cell growth in a cell viability assay, IC50=4.39183μM |
SANGER |
CAS-1 |
Growth inhibition assay |
|
|
Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=4.4023μM |
SANGER |
BB65-RCC |
Growth inhibition assay |
|
|
Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50=4.69952μM |
SANGER |
MRK-nu-1 |
Growth inhibition assay |
|
|
Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50=4.71792μM |
SANGER |
NCI-H1355 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50=4.87685μM |
SANGER |
KP-N-YS |
Growth inhibition assay |
|
|
Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50=4.92086μM |
SANGER |
MZ7-mel |
Growth inhibition assay |
|
|
Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50=5.09269μM |
SANGER |
NCI-H747 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50=5.74159μM |
SANGER |
C2BBe1 |
Growth inhibition assay |
|
|
Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50=5.78469μM |
SANGER |
RPMI-6666 |
Growth inhibition assay |
|
|
Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50=5.9621μM |
SANGER |
PSN1 |
Growth inhibition assay |
|
|
Inhibition of human PSN1 cell growth in a cell viability assay, IC50=6.16376μM |
SANGER |
TE-1 |
Growth inhibition assay |
|
|
Inhibition of human TE-1 cell growth in a cell viability assay, IC50=6.71768μM |
SANGER |
ETK-1 |
Growth inhibition assay |
|
|
Inhibition of human ETK-1 cell growth in a cell viability assay, IC50=7.6356μM |
SANGER |
ST486 |
Growth inhibition assay |
|
|
Inhibition of human ST486 cell growth in a cell viability assay, IC50=8.27227μM |
SANGER |
KU812 |
Growth inhibition assay |
|
|
Inhibition of human KU812 cell growth in a cell viability assay, IC50=8.38738μM |
SANGER |
EHEB |
Growth inhibition assay |
|
|
Inhibition of human EHEB cell growth in a cell viability assay, IC50=9.0509μM |
SANGER |
IMR-5 |
Growth inhibition assay |
|
|
Inhibition of human IMR-5 cell growth in a cell viability assay, IC50=9.28459μM |
SANGER |
BB49-HNC |
Growth inhibition assay |
|
|
Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=9.96548μM |
SANGER |
NCI-H1581 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=10.3373μM |
SANGER |
CP66-MEL |
Growth inhibition assay |
|
|
Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50=10.6469μM |
SANGER |
NMC-G1 |
Growth inhibition assay |
|
|
Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=11.0324μM |
SANGER |
SIMA |
Growth inhibition assay |
|
|
Inhibition of human SIMA cell growth in a cell viability assay, IC50=11.2916μM |
SANGER |
A101D |
Growth inhibition assay |
|
|
Inhibition of human A101D cell growth in a cell viability assay, IC50=11.8487μM |
SANGER |
IST-MEL1 |
Growth inhibition assay |
|
|
Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50=12.5986μM |
SANGER |
no-10 |
Growth inhibition assay |
|
|
Inhibition of human no-10 cell growth in a cell viability assay, IC50=13.1434μM |
SANGER |
KALS-1 |
Growth inhibition assay |
|
|
Inhibition of human KALS-1 cell growth in a cell viability assay, IC50=13.16μM |
SANGER |
GI-1 |
Growth inhibition assay |
|
|
Inhibition of human GI-1 cell growth in a cell viability assay, IC50=13.2491μM |
SANGER |
ONS-76 |
Growth inhibition assay |
|
|
Inhibition of human ONS-76 cell growth in a cell viability assay, IC50=13.3728μM |
SANGER |
D-247MG |
Growth inhibition assay |
|
|
Inhibition of human D-247MG cell growth in a cell viability assay, IC50=13.7709μM |
SANGER |
NCI-H446 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H446 cell growth in a cell viability assay, IC50=14.1409μM |
SANGER |
NALM-6 |
Growth inhibition assay |
|
|
Inhibition of human NALM-6 cell growth in a cell viability assay, IC50=14.2358μM |
SANGER |
SK-N-DZ |
Growth inhibition assay |
|
|
Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50=14.442μM |
SANGER |
QIMR-WIL |
Growth inhibition assay |
|
|
Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=14.5247μM |
SANGER |
MHH-NB-11 |
Growth inhibition assay |
|
|
Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50=14.6569μM |
SANGER |
A388 |
Growth inhibition assay |
|
|
Inhibition of human A388 cell growth in a cell viability assay, IC50=14.6758μM |
SANGER |
EVSA-T |
Growth inhibition assay |
|
|
Inhibition of human EVSA-T cell growth in a cell viability assay, IC50=15.2484μM |
SANGER |
JVM-2 |
Growth inhibition assay |
|
|
Inhibition of human JVM-2 cell growth in a cell viability assay, IC50=16.4704μM |
SANGER |
EW-16 |
Growth inhibition assay |
|
|
Inhibition of human EW-16 cell growth in a cell viability assay, IC50=17.7718μM |
SANGER |
CP67-MEL |
Growth inhibition assay |
|
|
Inhibition of human CP67-MEL cell growth in a cell viability assay, IC50=18.5863μM |
SANGER |
NB13 |
Growth inhibition assay |
|
|
Inhibition of human NB13 cell growth in a cell viability assay, IC50=19.0437μM |
SANGER |
NCCIT |
Growth inhibition assay |
|
|
Inhibition of human NCCIT cell growth in a cell viability assay, IC50=20.0093μM |
SANGER |
SNU-C2B |
Growth inhibition assay |
|
|
Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50=20.5124μM |
SANGER |
SK-NEP-1 |
Growth inhibition assay |
|
|
Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50=22.2335μM |
SANGER |
TE-6 |
Growth inhibition assay |
|
|
Inhibition of human TE-6 cell growth in a cell viability assay, IC50=22.3864μM |
SANGER |
HCE-4 |
Growth inhibition assay |
|
|
Inhibition of human HCE-4 cell growth in a cell viability assay, IC50=22.927μM |
SANGER |
TGBC1TKB |
Growth inhibition assay |
|
|
Inhibition of human TGBC1TKB cell growth in a cell viability assay, IC50=23.3177μM |
SANGER |
L-540 |
Growth inhibition assay |
|
|
Inhibition of human L-540 cell growth in a cell viability assay, IC50=23.3231μM |
SANGER |
8-MG-BA |
Growth inhibition assay |
|
|
Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50=23.9588μM |
SANGER |
OPM-2 |
Growth inhibition assay |
|
|
Inhibition of human OPM-2 cell growth in a cell viability assay, IC50=25.106μM |
SANGER |
MHH-PREB-1 |
Growth inhibition assay |
|
|
Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50=26.2134μM |
SANGER |
ALL-PO |
Growth inhibition assay |
|
|
Inhibition of human ALL-PO cell growth in a cell viability assay, IC50=26.6132μM |
SANGER |
LB771-HNC |
Growth inhibition assay |
|
|
Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50=27.8393μM |
SANGER |
NEC8 |
Growth inhibition assay |
|
|
Inhibition of human NEC8 cell growth in a cell viability assay, IC50=29.0389μM |
SANGER |
MSTO-211H |
Growth inhibition assay |
|
|
Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50=29.059μM |
SANGER |
ATN-1 |
Growth inhibition assay |
|
|
Inhibition of human ATN-1 cell growth in a cell viability assay, IC50=29.7028μM |
SANGER |
LB373-MEL-D |
Growth inhibition assay |
|
|
Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50=29.7129μM |
SANGER |
NB69 |
Growth inhibition assay |
|
|
Inhibition of human NB69 cell growth in a cell viability assay, IC50=30.374μM |
SANGER |
LOXIMVI |
Growth inhibition assay |
|
|
Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50=30.8334μM |
SANGER |
HC-1 |
Growth inhibition assay |
|
|
Inhibition of human HC-1 cell growth in a cell viability assay, IC50=32.8423μM |
SANGER |
SK-UT-1 |
Growth inhibition assay |
|
|
Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50=32.9447μM |
SANGER |
KARPAS-422 |
Growth inhibition assay |
|
|
Inhibition of human KARPAS-422 cell growth in a cell viability assay, IC50=33.2528μM |
SANGER |
KP-N-RT-BM-1 |
Growth inhibition assay |
|
|
Inhibition of human KP-N-RT-BM-1 cell growth in a cell viability assay, IC50=33.8198μM |
SANGER |
SIG-M5 |
Growth inhibition assay |
|
|
Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50=34.6805μM |
SANGER |
TE-11 |
Growth inhibition assay |
|
|
Inhibition of human TE-11 cell growth in a cell viability assay, IC50=38.0936μM |
SANGER |
RKO |
Growth inhibition assay |
|
|
Inhibition of human RKO cell growth in a cell viability assay, IC50=38.4067μM |
SANGER |
LS-411N |
Growth inhibition assay |
|
|
Inhibition of human LS-411N cell growth in a cell viability assay, IC50=38.8809μM |
SANGER |
OCUB-M |
Growth inhibition assay |
|
|
Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=40.2533μM |
SANGER |
OVCAR-4 |
Growth inhibition assay |
|
|
Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50=40.5786μM |
SANGER |
JiyoyeP-2003 |
Growth inhibition assay |
|
|
Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50=41.2672μM |
SANGER |
no-11 |
Growth inhibition assay |
|
|
Inhibition of human no-11 cell growth in a cell viability assay, IC50=41.8283μM |
SANGER |
NCI-H1694 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50=43.3351μM |
SANGER |
IST-SL1 |
Growth inhibition assay |
|
|
Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50=46.6838μM |
SANGER |
T cells |
Function assay |
|
|
Inhibition of anti-CD3/CD28-induced IL2 secretion in human T cells, IC50=1.9μM |
16884310 |
SJ-GBM2 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells |
29435139 |
A673 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
BT-37 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
SK-N-SH |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |